{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:52:09Z","timestamp":1781790729514,"version":"3.54.5"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI129649, 1R21AI179228"],"award-info":[{"award-number":["1R01AI129649, 1R21AI179228"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Prolonged daily tuberculosis therapy contributes to toxicity, poor adherence, and drug resistance. We developed rifampin (RIF)-loaded \u03b2-glucan-chitosan-poly (lactic co-glycolic) acid nanoparticles (\u03b2-C-P nanoparticles) for weekly pulmonary delivery and evaluated a hybrid dosing regimen in a BALB\/c\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      model. Weekly instilled RIF loaded 20% \u03b2-C-P nanoparticles combined with daily oral isoniazid (INH) and pyrazinamide (PZA) reduced lung and spleen bacterial burdens comparable to oral daily standard of care (RIF, INH, PZA) and were well tolerated, demonstrating preserved efficacy with reduced RIF dosing frequency.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00281-26","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:00:21Z","timestamp":1776679221000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Weekly pulmonary delivery of \u03b2-glucan-chitosan-poly(lactic co-glycolic) acid (\u03b2-C-P) nanoparticles with daily standard oral therapy achieves control of\n                    <i>Mycobacterium tuberculosis<\/i>\n                    in BALB\/c mice"],"prefix":"10.1128","volume":"70","author":[{"given":"Hilliard L.","family":"Kutscher","sequence":"first","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo","place":["Buffalo, USA"]},{"name":"Institute for Lasers, Photonics and Biophotonics, The State University of New York at Buffalo","place":["Buffalo, USA"]},{"name":"Department of Anesthesiology, The State University of New York at Buffalo","place":["Buffalo, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tamblin","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo","place":["Buffalo, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0410-5224","authenticated-orcid":true,"given":"Patrick","family":"Kenney","sequence":"additional","affiliation":[{"name":"Adult and Pediatric Infectious Disease, The State University of New York at Buffalo","place":["Buffalo, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5188-6786","authenticated-orcid":true,"given":"Jessica L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo","place":["Buffalo, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.54394\/CJQU6666"},{"key":"e_1_3_3_3_2","unstructured":"Global tuberculosis report 2023. 2023. G.W.H. Organization"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00309102"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v21i1.31"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmicr.2024.100295"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201509-632PS"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.4c00713"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2013.11.012"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202400057"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2391-8"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2576-9"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1095926"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01480-25"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101360"},{"key":"e_1_3_3_16_2","first-page":"357","article-title":"Nanotechnology based drug delivery system(s) for the management of tuberculosis","volume":"44","author":"Pandey R","year":"2006","unstructured":"Pandey R, Khuller GK. 2006. Nanotechnology based drug delivery system(s) for the management of tuberculosis. Indian J Exp Biol 44:357\u2013366.","journal-title":"Indian J Exp Biol"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S257758"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1007527204887"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.941077"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1013094112861"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.747799"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2004.11.003"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg477"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2003.07.001"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15875"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.01.038"},{"key":"e_1_3_3_27_2","first-page":"278","article-title":"Lactose-conjugated PLGA nanoparticles for enhanced delivery of rifampicin to the lung for effective treatment of pulmonary tuberculosis","volume":"64","author":"Jain SK","year":"2010","unstructured":"Jain SK, Gupta Y, Ramalingam L, Jain A, Jain A, Khare P, Bhargava D. 2010. Lactose-conjugated PLGA nanoparticles for enhanced delivery of rifampicin to the lung for effective treatment of pulmonary tuberculosis. PDA J Pharm Sci Technol 64:278\u2013287.","journal-title":"PDA J Pharm Sci Technol"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2011.1244"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.supplement_3.s428"},{"key":"e_1_3_3_30_2","volume-title":"StatPearls","author":"Beloor Suresh A","year":"2025","unstructured":"Beloor Suresh A. 2025. Rifampin. In StatPearls. StatPearls Publishing: Treasure Island (FL)."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00281-26","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00281-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:03:58Z","timestamp":1781787838000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00281-26"}},"subtitle":[],"editor":[{"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,3]]}},"alternative-id":["10.1128\/aac.00281-26"],"URL":"https:\/\/doi.org\/10.1128\/aac.00281-26","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"2026-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00281-26"}}